Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Recombinant human keratinocyte growth factor-2 (rhKGF-2), also known as fibroblast growth factor-10 (FGF-10), is a recombinant protein that acts as a potent mitogen for epithelial cells. It specifically binds to and activates the fibroblast growth factor receptor 2b (FGFR2b), which is expressed on the surface of various epithelial tissues, including the cornea and skin. Activation of this receptor triggers signaling cascades that promote the proliferation, migration, and survival of keratinocytes, thereby accelerating the repair of epithelial injuries. Developed by the Guangdong Jinan University Gene Medicine Engineering Research Center, rhKGF-2 is primarily being investigated for ophthalmic indications such as corneal epithelial defects, corneal abrasions, chemical burns, and dry eye syndrome. By facilitating rapid re-epithelialization of the ocular surface, rhKGF-2 aims to restore corneal integrity and prevent complications such as infection or scarring.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on recombinant human keratinocyte growth factor-2.